This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Following the acquisition of two cell analysis businesses in the past month, PerkinElmer officials said last week that they are bullish on that market for 2007, though they expect both acquisitions to be neutral or slightly accretive to earnings this year. The firm also announced that its fourth-quarter 2006 revenues increased 10 percent year over year to $427 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.